ID Design 2012/DOOEL Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2016 Jun 15; 4(2):219-225. http://dx.doi.org/10.3889/oamjms.2016.043 eISSN: 1857-9655 Basic Science
Hepatitis B Seroprotection and the Response to a Challenging Dose among Vaccinated Children in Red Sea Governorate 1
2*
2
2
2
Samia M. Sami , Iman I. Salama , Ghada A. Abdel-Latif , Lobna A. El Etreby , Ahmed I. Metwally , Naglaa F. Abd El 3 haliem 1
2
National Research Center, Child Health, Cairo, Egypt; National Research Center, Community Medicine Research, Cairo, 3 Egypt; Faculty of Medicine, Al Azhar University - Microbiology and Immunology, Cairo, Egypt
Abstract Citation: Sami SM, Salama II, Abdel-Latif GA, El Etreby LA, Metwally AI, Abd El Haliem NF. Hepatitis B Seroprotection and the Response to a Challenging Dose among Vaccinated Children in Red Sea Governorate. Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219225. http://dx.doi.org/10.3889/oamjms.2016.043 Keywords: Anamnestic response; Booster Seroprotection; HBV vaccine; Children; Egypt.
dose;
*Correspondence: Iman Ibrahim Salama. National Research Centre, 32 El Bouhoth st., El Dokki, Giza, Egypt. Phone number: +2 01005401725 . Fax number: +2 27546389. E-mail: [email protected] Received: 04-Mar-2016; Revised: 25-Mar-2016; Accepted: 26-Mar-2016; Online first: 24-May-2016 Copyright: © 2016 Samia M. Sami, Iman I. Salama, Ghada A. Abdel-Latif, Lobna A. El Etreby, Ahmed I. Metwally, Naglaa F. Abd El haliem. This is an openaccess article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Competing Interests: The authors have declared that no competing interests exist.
AIM: To assess the long-term effectiveness of hepatitis B virus vaccine and the need for a booster dose among children who received three doses of vaccine during infancy in Red Sea Governorate. METHODS: A cross-sectional study was performed. Interviews with children (9 months to 16 years) and parents were done. Blood samples to assess Hepatitis B markers were tested. Children showing no seroprotection received a booster dose to assess their anamnestic response after four weeks and one year later. RESULTS: None of the participants had evidence of chronic Hepatitis B. The seroprotection rate was 23.3% and it significantly decreased with age. Multivariate logistic analysis revealed that older age was the significant predicting variable for having no seroprotective level, while baseline antiHBs level < 3.3 IU/L was the predicting variable for not developing early anamnestic response or loss of late anamnestic response. CONCLUSION: Long-term immunity persists among children who received complete series of hepatitis B vaccination during infancy even in absence or reduction of anti-HBs over time. Therefore, a booster dose is not necessary to maintain immunity till the age of sixteen.
Introduction HBV infection is a leading cause of acute and chronic liver disease, cirrhosis and hepatocellular carcinoma worldwide. WHO estimates that globally, about 2 billion people have been infected with hepatitis B virus, more than 350 million are chronically infected, and nearly 1 million die every year from acute or chronic sequelae of primary infection with the disease [1, 2]. In Egypt, 75%–85% of patients with the chronic liver disease have HBV or HCV infection as a contributing cause [3]. Mass vaccination of neonates and preschool children has been strongly recommended by the WHO [4, 5]. Hepatitis B vaccines are highly effective and safe and the public should be educated
about the importance and necessity of hepatitis B prevention by vaccination [6, 7]. It has been demonstrated that 90–99% of healthy neonates, children, adolescents, and adults develop protective levels of anti-HBs following a standard vaccination course with hepatitis B vaccine. Serum levels of anti-HBs ≥ 10 IU/L are considered to be protective against HBV infection [7-9]. Loss of detectable concentrations of antibodies (anti-HBs) to hepatitis B surface antigen (HBsAg) does not necessarily indicate loss of immunity. The presence of HBV-specific immune memory can be demonstrated by administering a challenging (booster) dose of vaccine and measuring anti-HBs response. A rapid increase in anti-HBs represents an anamnestic response and is considered to indicate the presence of HBV-specific immune memory [10].
_______________________________________________________________________________________________________________________________ Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219-225.
219
Basic Science _______________________________________________________________________________________________________________________________
In Egypt, HBV vaccination was included in 1992 in the Expanded Program on Immunization (EPI) with injections at 2, 4 and 6 months of age using the recombinant vaccine. The Ministry of Health and Population conducted a wide range of prophylactic strategies to control viral hepatitis. It was reported that the prevalence of hepatitis B surface antigen (HBsAg) positivity among healthy individuals decreased from 10.1% in 1985 to 1.18% in 2008, and the frequency of acute HBV infection as a cause of symptomatic hepatitis decreased significantly from 43.4% in 1983 to 28.5% in 2002 [11, 12]. The aim of the present study is to assess the long-term effectiveness of HBV vaccine and the need for a booster dose among fully vaccinated children during infancy in Red Sea Governorate.
Subjects and Methods The present study is a part of a national community based multi-stage cluster sampling design carried out in the period from July 2010 to June 2013 in 6 governorates representing all geographic regions of Egypt. For sampling process and cluster selection, probability proportional to size sampling was used. The sample frame for the current survey was based on the most recent population census 2006. According to the population size of each governorate, the number of participating clusters was identified in each governorate. First, implicit stratification by geographic location in each governorate, lists of shakhas, medinas, and villages were arranged in serpentine order geographically. This stratification was done independently for urban and rural areas. A sampling interval was calculated and accordingly, a random number was selected using a table of random numbers. From these lists, areas such as villages or city blocks were selected. In each selected area, lists of child health center (MCH), kindergarten and school facilities were identified and 5 facility clusters were randomly selected. The current work presented the part of the project results concerning Red Sea Governorate. From this governorate, 189 children from Hurghada were recruited. The study was conducted at facility levels, where 5 facilities (one maternal and child health center (MCH) or health unit, one kindergarten and 3 schools (1 primary, 1 preparatory and 1 secondary school) were randomly selected from each area according to the age of the targeted children. The study protocol was approved by the ethical committees of Ministry of Health, National Research Center and Ministry of Education. A closeended questionnaire was designed and tested. For quality assurance, training sessions for supervisors,
interviewers and Ministry of Health staff in Red Sea governorate were carried out. Peel-off barcode sheets were prepared and used for easy tracking of blood samples and laboratory results. Inclusion criteria were children aged from 9 months to 16 years and had received the full 3 compulsory doses of HBV vaccine during infancy. Signed written consents were obtained from each guardian Face to face interview was carried out with the parents or caretakers of the children. Adolescents above 10 years were also interviewed after their verbal assents which were obtained in the presence of their parents or class teachers. The questionnaire was used to collect data about child age, sex, date of birth and other demographic and socioeconomic variables. Data were also collected concerning children's' HBV vaccination and the available vaccination cards were revised for date and dose intervals of HBV vaccine. Socioeconomic status (SES) was determined according to Fahmy and El Sherbiny [13]. It depends on parents’ education, maternal working status, water source, sewage disposable, and availability of electricity and some modification of family income. Non-responders for the booster dose were further given 2 additional doses of HBV vaccine with 2 months interval in between. Out of 88 children proved to have nonseroprotective levels, 45 children participated and accepted to receive a booster dose of 10 μg monovalent Euvax HB vaccine intramuscularly in the front of the left thigh for children < 3 years and in the deltoid muscle for older children. A blood sample was withdrawn from each child for quantitative detection of anti-HBs one month and one year post–booster in order to assess their early and late anamnestic responses respectively. An anamnestic response was defined as rising in anti-HBs to ≥10 IU/L [14]. Three children who did not develop post-booster antiHBs level ≥ 10 IU/L were then offered two additional doses of Euvax HB vaccine (2nd vaccination series) 1 and 6 months post booster. One month later, a blood sample was withdrawn from only 2 children for quantitative detection of anti-HBs to assess their immune response.
Blood sampling and Laboratory Analysis About 3-5 ml blood sample was withdrawn aseptically from each participant. Serum samples were aliquoted into two labeled sterile cryo tubes and were stored at –20°C until laboratory examination. HBV markers detection was carried out in the Virology lab in the Microbiology Department,Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt. It was carried out using commercially available enzyme-linked immunoassays (ELISA, DiaSorinItaly) and according to the manufacturer instructions. Quantitative detection of serum anti-HBs and qualitative determination of serum Total HBV core antibody (anti-HBc) and hepatitis B surface antigen (HBsAg) was assessed. According to international
_______________________________________________________________________________________________________________________________ 220
http://www.mjms.mk/ http://www.id-press.eu/mjms/
Sami et al. Hepatitis B Seroprotection among Vaccinated Children in Red Sea Governorate _______________________________________________________________________________________________________________________________
standards, anti-HBs ≥ 10 IU/L was considered to be protective against HBV infection [14, 15]. Vaccines that developed an anti HBs level between 10-100 IU/L after the full vaccination dose are referred to as low responders while those above 100 IU/L are good responders [16]. Sero-positivity is defined as cutoff anti-HBs of 3.3 IU/L [17]. Breakthrough infection was defined as anti-HBs seropositivity in vaccinated subjects who were not chronically infected [18].
seroprotective level (< 10IU/L). As regards early postbooster anamnestic response, 75.6% developed a good anamnestic response, 17.8% developed low anamnestic response (10-99 IU/L) and 6.7% were non-responders. Table 1: Sero-protection rate among the studied children
Risk Factor
Data analysis and presentation Data entry was carried out on excel sheet and statistical analysis was performed using SPSS software program version 18.0 (SPSS Inc., Chicago). The geometric mean titer (GMT) was calculated to indicate the central tendency of anti-HBs titers in consideration of the skewed distribution of antiHBs level. For the calculation of the GMT, children who had an undetectable anti-HBs titer were assigned a nominal serum anti-HBs titer value of 0.05 IU/l [13]. The w2-test was performed for qualitative data and was presented by numbers and percentages. The ttest was performed for comparison between two means and one-way analysis of variance for more than two means. When data were not normally distributed, Mann-Whitney U test was used. The multivariate logistic analysis was performed to predict the risk factors significantly associated with non seroprotection and non-development of early and late anamnestic response. P value was considered statistically significant when its value was less than 0.05 and considered statistically highly significant when its value was less than 0.01.
Total n= 189
Baseline anti-HBs level (IU/L) Non seroSero-protection protection Anti-HBs ≥10 Anti-HBs -2 159 76 (47.8) 83 ≤ -2 22 8 (36.4) 14 WAZ > -2 176 81 (46.0) 95 ≤ -2 3 1 (33.3) 2 Lactation Breast fed 134 57 (42.5) 77 Artificially fed 29 17 (58.6) 12 History of hospital admission Yes 58 33 (56.9) 25 No 131 55 (42.0) 76 History of abscess incision Yes 12 5 (41.7) 7 No 174 82 (47.1) 92 HAZ = height for age Z score; WAZ = weight for age Z score.
(54.0) (52.8) (82.8) (56.8) (34.0) (39.3) (51.4) (53.2) (60.0)
0.870
< 0.001
0.317
(52.2) (63.6)
0.736
(54.0) (66.7)
0.189
(57.5) (41.4)
0.272
(43.1) (58.0)
0.058
(58.3) (52.9)
0.714
Out of 42 children who developed early, anamnestic response 41 (97.6%) were followed up one year later to assess the persistence of response (late anamnestic response). It was found that 31 children (75.6%) still retained their anamnestic response (anti-HBs ≥10IU/L) while 10 children (24.4%) had lost their protective level.
Results The total number of studied children was 189 (100 boys and 89 girls) aged 9 months to 16 years with a mean age of 9.6 years. None of the participants had an evidence of chronic HBV or breakthrough infection. Table 1 shows that the nonseroprotection level significantly increased with age (it was 17.2% for the age group < 5 years and 66% for the age group >10 years, P < 0.05). There was no significant difference in the seroprotection level as regards gender, socioeconomic status, and other studied variables. Only 45 children with non-seroprotection level received the booster dose and 93.4% of them developed an anamnestic response. Figure 1 presents the baseline seroprotection rate and postbooster anamnestic response rate among the studied children. At baseline, out of 189 studied children, only 44 (23.3%) had a good level of seroprotection (antiHBs ≥ 100 IU/L) and 88 (46.6%) had a non-
Figure 1: Baseline seroprotection and early anamnestic response rates among the studied children
Meanwhile, the two children who received the 2nd vaccination series developed a good level of
_______________________________________________________________________________________________________________________________ Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219-225.
221
Basic Science _______________________________________________________________________________________________________________________________
immune response (anti-HBs ≥100 IU/L). Both were boys aged 11 years. Table 2: Anamnestic response and anti-HBs GMT in relation to gender, age, and pre-booster level
N = 189 GMT ± SD
Early Anamnestic Response N = 45 GMT ± SD
Late Anamnestic Response N = 41 GMT ± SD
9.8 ± 13.5 12.1 ± 14.9 0.589
209.6 ± 12.2 249.0 ± 9.2 0.624
95.5 ± 21.3 39.3 ± 2.3 0.117
45.7 ± 9.5 3.6 ± 10.9 10 years P value Pre-booster level
Table 2 presents baseline, early and late anamnestic response anti-HBs GMT in relation to gender, age, and pre-booster level. There was no difference between both sexes as regard prebooster and post- booster (early and late anamnestic response) GMT anti-HBs. While children aged ≤ 10 years had significantly higher pre-booster antiHBs GMT than older children, post-booster (early and late) GMT anti- HBs did not differ among both age groups. When pre-booster non-seroprotection antiHBs levels were divided into seronegative (< 3.3 IU/L) and seropositive (≥ 3.3 IU/L), the post-booster early anamnestic response GMT was significantly higher among children with seropositive level of antiHBs than among those with seronegative level of antiHBs (848.6 ± 1.3 & 64.3 ± 18.0 respectively) P = 0.004. However, there was no statistically significant difference between both groups for late anamnestic response GMT. Table 3: Predictors of not seroprotection, early and late anamnestic responses using logistic analysis 95% CI Lower Upper
P value
® 3.616 8.509
1.363 3.648
9.592 19.848
0.010 < 0.001
® 4.7
2.1
10.4
< 0.001
Variables
AOR
At Baseline Age group < 5 years 5-10 years >10 years Early Anamnestic Response Baseline anti-HBs level ≥ 3.3 IU/L < 3.3 IU/L
Late Anamnestic response Baseline anti-HBs level ® ≥ 3.3 IU/L 1.4 3.0 < 3.3 IU/L 2.0 ®: reference group; AOR: adjusted odds ratio; CI: confidence interval.
< 0.001
Multivariate logistic analysis revealed that older age was the only significant predicting variable for having no seroprotective level, with AOR = 3.6 and 8.5 among children aged 5-10 and older age respectively compared to those < 5 years, P < 0.01. The significant predicting variable for not developing
an early anamnestic response or loss of late anamnestic response was baseline anti-HBs level < 3.3 IU/L with AOR 4.7 & 2.0 respectively and P70% [25, 26]. The seroprotection rate was higher among boys (54.0%) than girls (52.8%) and among children with higher socioeconomic status (60.0%) compared with others with very low socioeconomic status (39.4%), but with no statistically significant difference. Similarly, no statistically significant differences were reported as regards gender [5, 21, 22, 24]. However, Sami et al found that in Gharbeya Governorate in Lower Egypt among 762 children, the non seroprotection rate was significantly higher among girls (50.1%) compared to boys (33.6%) (P 6 years, while no statistical difference was found among children < 6 years [28]. The present study showed that 46.6% of studied children had non-seroprotective levels of anti-
_______________________________________________________________________________________________________________________________ 222
http://www.mjms.mk/ http://www.id-press.eu/mjms/
Sami et al. Hepatitis B Seroprotection among Vaccinated Children in Red Sea Governorate _______________________________________________________________________________________________________________________________
HBsat baseline and 93.4% of those receiving the booster dose developed an anamnestic response. Seventy-five percent of them developed good anamnestic response (anti-HBs ≥ 100 IU/L) and 6.7% were non-responders. Similarly, in Egypt, it was found that 91.7% of non-seroprotected children developed anamnestic response and 77.8% of them reported good response [27]. Moreover, Eldesoky et al found that 97.2% of the non-seroprotected children developed good anamnestic response [7]. A Turkish and an Italian study also reported that over 95% of non-seroprotected children developed an anamnestic response post booster [21, 22]. A lower percentage of children developed a postbooster anamnestic response in Iran (78.1%) and in Taiwan [24, 29]. Booster doses of hepatitis B vaccine after primary vaccination in immune competent individuals are currently not recommended by either the WHO or the European Consensus group on Hepatitis B Immunity. The decrease of antibody concentrations below seroprotection level or even below detection levels is not considered as an indicator of loss of protection [30]. The real threat may emerge when the vaccinated subjects begin to engage in high-risk behaviors for HBV transmission in areas of high endemicity. Boosters for certain highrisk groups or for individuals living in the areas of high endemicity may be a reasonable alternative [31-33]. In this study, post booster anamnestic was detected among 100% of non-seroprotected children having pre-booster level ≥ 3.3 IU/l compared to only 90.3% of those having pre-booster level < 3.3 IU/l (P > 0.05). Similarly but to a less extent, Steiner et al, reported that 90.5% of children who had antiHBs antibody concentrations > 3.3 IU/l reached the seroprotection level after receiving the booster dose compared to 81.0% of seronegative children [34]. In the current study, girls had higher prebooster and post-booster anti-HBs GMT compared with boys but with no statistically significant difference between both sexes (P > 0.05]. While children aged ≤ 10 years had significantly higher pre-booster antiHBs GMT than those aged >10 years (P < 0.05], but there was no difference between both age groups in the post-booster anti-HBs GMT. These results are similar to those of other studies in Alaska, Turkey, and Iran which found that pre-booster anti-HBs GMT significantly decreased with age [10, 21, 24). However, in two Iranian studies, it was found that the post-booster anti-HBsGMT among girls was significantly higher than among boys (P < 0.05] [23, 24]. The statistically significant difference between the mean antibody concentration before and after the booster dose shows the vigorous response of the immune system to the booster and suggests that the immunologic memory is good [24]. In the current study, 100% of the children ≤ 10 years and 91.1% of adolescents developed anamnestic response (P > 0.05). Similarly, in Alaska, 99% of children and 83% of adolescents [10] and
100% of children in Taiwan [32] developed an anamnestic response to a booster dose. Similar results were also reported by [21, 24]. They also found that there was no significant difference in postbooster anamnestic response rate as regards age. In contrast, the anamnestic response rate in Alaskan children decreased according to increasing age [10]. In the current study, the anamnestic response rate to the booster dose did not vary between boys and girls (91.3% and 95.5% respectively, P > 0.05). Similarly, in Gharbeya governorate, the anamnestic response rate was 90.1% among boys and 92.5% among girls, P > 0.05 [27]. On the contrary, Su et al found that Taiwanese adolescent females always had a greater anamnestic response rate than males (P < 0.001) [35]. In the present study, 75.6% of children still retained their anamnestic response after one year post- booster. This was also found in a study in Gambia where 80% of boosted participants still had detectable antibodies [8] and in Canada where 99.3% of subjects in the Engerix-B 10 [mu]g (EB) group and 100% in the Recombivax-HB 2.5 [mu]g (RB) group had detectable anti-HBs one year after the booster [31]. In this study after the booster dose was administered, 6.7% of children were non-responders and two out of the three children who failed to generate an early anamnestic response after receiving the booster dose, were offered another two doses of recombinant HBV vaccine. While 3% of Italian children and 4% of Italian recruits remained negative for anti-HBs, they offered to complete the second course of vaccination with two additional vaccine doses given at 1 and 6 months after the first booster injection [22]. Also, 3% of boosted participants in Gambia did not mount a detectable antibody response following a booster dose of HBV [8]. Samandari et al and Su et al reported that 28.7% and 31% of Alaskan and Taiwanese adolescents respectively did not respond to a booster dose. [10, 35] Logistic analysis for determining predictors of not seroprotection revealed that older age was the only significant predicting variable for having no seroprotective level while significant predicting variable for not developing an early anamnestic response or loss of late anamnestic response was baseline anti-HBs level < 3.3 IU/L. On the contrary, there was no significant difference as regards HBV booster non-response in subjects below or above 16 years of age in a study by Lu et al [32.] In another study by Wang and Lin, risk of non-response to booster vaccination was highest among adolescents who smoked cigarettes and chewed betel- quid [36]. The study concluded that long-term immunity exists among children who had complete series of hepatitis B vaccination during infancy even in the case of reduced or absent anti-HBs over time. HBV vaccine
_______________________________________________________________________________________________________________________________ Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219-225.
223
Basic Science _______________________________________________________________________________________________________________________________
is highly protective against HBV infection as evidenced by the absence of HBV infection in the vaccinated groups. The longer the time lapse after vaccination, the lower the seroprotection rate and the lower the mean anti-HBs. More than 93% of vaccinated individuals who lost protective levels of antibody developed a rapid anamnestic response when boosted and this indicates the presence of immune memory. Therefore, using routine booster doses of hepatitis B vaccine is not necessary to sustain at least 16 years of protection in immunized individuals.
results from a case–control study in Greater Cairo. International Journal of Epidemiology. 2009;38:757–765. http://dx.doi.org/10.1093/ije/dyp194 PMid:19420088
References
16. Shouval D. Hepatitis B vaccines. Journal of Hepatology. 2003;39:S70-76. http://dx.doi.org/10.1016/S0168-8278(03)00152-1
1. Huang C, Dai C, Chuang W, Ho C, Wu T, Hou N, Wang C, Hsieh M, Huang J, Lin Z, Chen S, Hsieh M, Wang L, Tsai J, Chang W, Yu M. HBV infection in indigenous children, 20 years after immunization in Taiwan: A community-based study. Elsevier Inc. Preventive Medicine. 2009;48:397–400. http://dx.doi.org/10.1016/j.ypmed.2009.02.002 PMid:19463479
17. Burgessa MA, McIntyrea PB, Hellardb M, Ruffc TA, Lefevred I, Bockd HL. Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine. 2010;28:2222–2226. http://dx.doi.org/10.1016/j.vaccine.2009.12.053 PMid:20056187
2. World Health Organization (WHO). Hepatitis B.1. Geneva, (WHO Fact sheet, No. 204. (http://www.who.int/mediacentre/factsheets/fs204/en/index.html, accessed 18 May 2009). 3. Talaat M, El-Sayed N, Kandeel A, Azab MA, Afifi S, Youssef FG, Ismael T, Hajjeh R, Mahoney FJ. Sentinel surveillance for patients with acute hepatitis in Egypt, 2001–04. Eastern Mediterranean Health Journal (EMHJ). 2010;16(2).
12. Youssef A, Yano Y, ZakiM E, Utsumi T, Hayashi Y. Characteristics of hepatitis viruses among Egyptian children with acute hepatitis. 2013: 1459-1465. 13. Fahmy SI, El-Sherbiny AF. Determining simple parameters for social classifications for health research. The Bulletin of the High institute of Public Health. 1983;18(5):95-103. 14. World Health Organization (WHO). Hepatitis B. WHO/CDS/CSR/mLYO/. 2002;2:1–76. 15. Zanetti A, Parlato A, Romanò L, Desole MG, Ferrera G, Giurdanella F et al. Challenge with a hepatitis B vaccine in two cohorts of 4-7-year-old children primed with hexavalent vaccines: an open-label,randomised trial in Italy. Vaccine. 2012; 30(39): 5770-5. http://dx.doi.org/10.1016/j.vaccine.2012.06.078 PMid:22789511
18. Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, JengBarry A, Sidibeh M, Jatta A, Moore SE, Hall AJ, Whittle H. Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One. 2013; 8(3):e58029. http://dx.doi.org/10.1371/journal.pone.0058029 PMid:23533578 PMCid:PMC3606345 19. Banatvala J. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000;355:561–65. http://dx.doi.org/10.1016/S0140-6736(99)07239-6
4. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B Virus Infection: Epidemiology and Vaccination. From the Epidemiology Branch, Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Accepted for publication March 28, 2006.
20. Salama II, Sami SM, Salama SI, Foud WA, Abdel Hamid AT, Said ZN. Persistence of protection to hepatitis B vaccine and response to booster dose among children and adolescents in Dakahleya- Egypt. Egyptian Journal of Immunology, 2014;21 (1): 13-26. PMid:25204041
5. Han K, Shao X, Zheng H, Wu C, Zhu J, Zheng X, Zhang Y. Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule. Human Vaccines & Immunotherapeutics. 2012;8:12,1845–1849. http://dx.doi.org/10.4161/hv.21818 PMid:22906933 PMCid:PMC3656074
21. Aypak C, Yüce A, Yıkılkan H, Görpelioğlu S. Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children. Eur J Pediatr. 2012;171:1761–1766. http://dx.doi.org/10.1007/s00431-012-1815-4 PMid:22895894
6. Chen D. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. Journal of Hepatology. 2009; 50:805–816. http://dx.doi.org/10.1016/j.jhep.2009.01.002 PMid:19231008 7. Eldesoky A, Mosaad Y, Zakria Y, Hamdy S. Protective immunity after hepatitis B vaccination. 2009; 10(2):68–71. 8. van der Sande MAB, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey SJ, Jeffries D, Hall AJ, Whittle HC. Long-Term Protection against Carriage of Hepatitis B Virus after Infant Vaccination. The Journal of Infectious Diseases. 2007; 193:1528–35. http://dx.doi.org/10.1086/503433 PMid:16652281 9. Zhu C, Liu P, Chen T, Ni Z, Lu L, Huang F, Lu J, Sun Z, Qu C. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine. 2011;29:7835–7841. http://dx.doi.org/10.1016/j.vaccine.2011.07.098 PMid:21816197 10. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, Bell BP. Differences in Response to a Hepatitis B Vaccine Booster Dose Among Alaskan Children and Adolescents Vaccinated During Infancy. Pediatrics. 2007;120(2): e373-e381. http://dx.doi.org/10.1542/peds.2007-0131 PMid:17636112 11. Jimenez AP, Sharaf El-Din N, El-Hoseiny M, El-Daly M, AbdelHamid M, El Aidi S, Sultan Y, El- Sayed N, Mohamed MK, Fontanet A. Community transmission of hepatitis B virus in Egypt:
22. Zanetti AR, Mariano A, Roman L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, Parlato A, Zamparo E, Zotti C, Stroffolini T, Mele A, and the Study Group. Long- term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366: 1379–84. http://dx.doi.org/10.1016/S0140-6736(05)67568-X 23. Hassan S, Ziba F. Antibody titre in Iranian children 6 years after hepatitis B vaccine administration. Vaccine. 2007; 25 (17):3511-4. http://dx.doi.org/10.1016/j.vaccine.2005.09.037 PMid:17400337 24. Yazdanpanah B, Safari M, Yazdanpanah S. Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran. Hepatitis Monthly. 2010;10(1):17-21. PMid:22308120 PMCid:PMC3270339 25. Liop LG, Alcoverro AA, Mas PC, Benedito MAR, Juan CG. [Anti-HBs titres after a vaccination program in children and adolescents. Should a booster dose be given?]. An Esp Pediatr. 2001; 54(1):32-7. http://dx.doi.org/10.1016/S1695-4033(01)786468 26. Behjati M, Mirhoseini N, Ayatollahi J. [A Survey of immune status of primary school age children, 7 years post hepatitis B vaccination]. J Shaheed Sadoughi Univ Med Sci. 2002;10(3):3-7. 27. Sami SM, Salama II, Rabah TM, El Etreby LA, Abdel Halim NF, Hemeida SA. Hepatitis B long-termseroprotection and the response to a challenging dose among vaccinated children in
_______________________________________________________________________________________________________________________________ 224
http://www.mjms.mk/ http://www.id-press.eu/mjms/
Sami et al. Hepatitis B Seroprotection among Vaccinated Children in Red Sea Governorate _______________________________________________________________________________________________________________________________
Gharbeya Governorate. Medical Research Journal. 2013;12:81– 87. http://dx.doi.org/10.1097/01.MJX.0000438131.28694.35 28. El-Sayed B, El-Guindi M, El-Shaarawy A, Salama EI, Sobhy GA. Long-term immunogenicity of hepatitis B vaccination in children. Zagazig J Occup Health Safety. 2009;2:17–28. 29. Wang L-Y, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBsnegative adolescents who had received primary vaccination 16 years ago. Vaccine. 2007; 7160– 7167. http://dx.doi.org/10.1016/j.vaccine.2007.07.022 PMid:17707557 30. Poorolaja lJ, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-termprotection provided by hepatitis B vaccine and need for booster dose: A meta-analysis. Vaccine. 2010;28:623–631. http://dx.doi.org/10.1016/j.vaccine.2009.10.068 PMid:19887132 31. Bernard D, Vladimir G, Nicole B, Philippe DW, Richard M, Gisele T, Gaston DS. Comparative Long Term Immunogenicity of Two Recombinant Hepatitis B Vaccines and the Effect of a Booster Dose Given After Five Years in a Low Endemicity Country. Pediatric Infectious Disease Journal. 2005;24(3):213-218. http://dx.doi.org/10.1097/01.inf.0000154329.00361.39 32. Lu CY1, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, Su IJ, Kuo HS, Huang LM, Chen DS, Lee CY Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis. 2008;197(10):1419-26. http://dx.doi.org/10.1086/587695 PMid:18444799 33. Saygun O, Eyigun CP, Avci IY, Kisa U, Pahsa A. Investigation (In Vivo and In Vitro) of Booster Dose Vaccine Requirement for Long-Term Protection against Hepatitis B Virus Infection Turk J Med Sci. 2009;39(2): 173-177. 34. Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet J-M, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infectious Diseases 2010. 2010; licensee Bio Med Central Ltd. http://www.biomedcentral.com/1471-2334/10/9. 35. Su FH, Cheng SH, Li CY, Chen JD, Hsiao CY, Chien CC, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine. 2007;25:8085–8090. http://dx.doi.org/10.1016/j.vaccine.2007.09.013 PMid:17920732 36. Wang LY, Lin HH. Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Journal of Hepatology. 2007;46:1018–1025. http://dx.doi.org/10.1016/j.jhep.2007.01.022 PMid:17399842
_______________________________________________________________________________________________________________________________ Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219-225.
225
Hepatitis B Seroprotection and the Response to a Challenging Dose among Vaccinated Children in Red Sea Governorate 1
2*
2
2
2
Samia M. Sami , Iman I. Salama , Ghada A. Abdel-Latif , Lobna A. El Etreby , Ahmed I. Metwally , Naglaa F. Abd El 3 haliem 1
2
National Research Center, Child Health, Cairo, Egypt; National Research Center, Community Medicine Research, Cairo, 3 Egypt; Faculty of Medicine, Al Azhar University - Microbiology and Immunology, Cairo, Egypt
Abstract Citation: Sami SM, Salama II, Abdel-Latif GA, El Etreby LA, Metwally AI, Abd El Haliem NF. Hepatitis B Seroprotection and the Response to a Challenging Dose among Vaccinated Children in Red Sea Governorate. Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219225. http://dx.doi.org/10.3889/oamjms.2016.043 Keywords: Anamnestic response; Booster Seroprotection; HBV vaccine; Children; Egypt.
dose;
*Correspondence: Iman Ibrahim Salama. National Research Centre, 32 El Bouhoth st., El Dokki, Giza, Egypt. Phone number: +2 01005401725 . Fax number: +2 27546389. E-mail: [email protected] Received: 04-Mar-2016; Revised: 25-Mar-2016; Accepted: 26-Mar-2016; Online first: 24-May-2016 Copyright: © 2016 Samia M. Sami, Iman I. Salama, Ghada A. Abdel-Latif, Lobna A. El Etreby, Ahmed I. Metwally, Naglaa F. Abd El haliem. This is an openaccess article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Competing Interests: The authors have declared that no competing interests exist.
AIM: To assess the long-term effectiveness of hepatitis B virus vaccine and the need for a booster dose among children who received three doses of vaccine during infancy in Red Sea Governorate. METHODS: A cross-sectional study was performed. Interviews with children (9 months to 16 years) and parents were done. Blood samples to assess Hepatitis B markers were tested. Children showing no seroprotection received a booster dose to assess their anamnestic response after four weeks and one year later. RESULTS: None of the participants had evidence of chronic Hepatitis B. The seroprotection rate was 23.3% and it significantly decreased with age. Multivariate logistic analysis revealed that older age was the significant predicting variable for having no seroprotective level, while baseline antiHBs level < 3.3 IU/L was the predicting variable for not developing early anamnestic response or loss of late anamnestic response. CONCLUSION: Long-term immunity persists among children who received complete series of hepatitis B vaccination during infancy even in absence or reduction of anti-HBs over time. Therefore, a booster dose is not necessary to maintain immunity till the age of sixteen.
Introduction HBV infection is a leading cause of acute and chronic liver disease, cirrhosis and hepatocellular carcinoma worldwide. WHO estimates that globally, about 2 billion people have been infected with hepatitis B virus, more than 350 million are chronically infected, and nearly 1 million die every year from acute or chronic sequelae of primary infection with the disease [1, 2]. In Egypt, 75%–85% of patients with the chronic liver disease have HBV or HCV infection as a contributing cause [3]. Mass vaccination of neonates and preschool children has been strongly recommended by the WHO [4, 5]. Hepatitis B vaccines are highly effective and safe and the public should be educated
about the importance and necessity of hepatitis B prevention by vaccination [6, 7]. It has been demonstrated that 90–99% of healthy neonates, children, adolescents, and adults develop protective levels of anti-HBs following a standard vaccination course with hepatitis B vaccine. Serum levels of anti-HBs ≥ 10 IU/L are considered to be protective against HBV infection [7-9]. Loss of detectable concentrations of antibodies (anti-HBs) to hepatitis B surface antigen (HBsAg) does not necessarily indicate loss of immunity. The presence of HBV-specific immune memory can be demonstrated by administering a challenging (booster) dose of vaccine and measuring anti-HBs response. A rapid increase in anti-HBs represents an anamnestic response and is considered to indicate the presence of HBV-specific immune memory [10].
_______________________________________________________________________________________________________________________________ Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219-225.
219
Basic Science _______________________________________________________________________________________________________________________________
In Egypt, HBV vaccination was included in 1992 in the Expanded Program on Immunization (EPI) with injections at 2, 4 and 6 months of age using the recombinant vaccine. The Ministry of Health and Population conducted a wide range of prophylactic strategies to control viral hepatitis. It was reported that the prevalence of hepatitis B surface antigen (HBsAg) positivity among healthy individuals decreased from 10.1% in 1985 to 1.18% in 2008, and the frequency of acute HBV infection as a cause of symptomatic hepatitis decreased significantly from 43.4% in 1983 to 28.5% in 2002 [11, 12]. The aim of the present study is to assess the long-term effectiveness of HBV vaccine and the need for a booster dose among fully vaccinated children during infancy in Red Sea Governorate.
Subjects and Methods The present study is a part of a national community based multi-stage cluster sampling design carried out in the period from July 2010 to June 2013 in 6 governorates representing all geographic regions of Egypt. For sampling process and cluster selection, probability proportional to size sampling was used. The sample frame for the current survey was based on the most recent population census 2006. According to the population size of each governorate, the number of participating clusters was identified in each governorate. First, implicit stratification by geographic location in each governorate, lists of shakhas, medinas, and villages were arranged in serpentine order geographically. This stratification was done independently for urban and rural areas. A sampling interval was calculated and accordingly, a random number was selected using a table of random numbers. From these lists, areas such as villages or city blocks were selected. In each selected area, lists of child health center (MCH), kindergarten and school facilities were identified and 5 facility clusters were randomly selected. The current work presented the part of the project results concerning Red Sea Governorate. From this governorate, 189 children from Hurghada were recruited. The study was conducted at facility levels, where 5 facilities (one maternal and child health center (MCH) or health unit, one kindergarten and 3 schools (1 primary, 1 preparatory and 1 secondary school) were randomly selected from each area according to the age of the targeted children. The study protocol was approved by the ethical committees of Ministry of Health, National Research Center and Ministry of Education. A closeended questionnaire was designed and tested. For quality assurance, training sessions for supervisors,
interviewers and Ministry of Health staff in Red Sea governorate were carried out. Peel-off barcode sheets were prepared and used for easy tracking of blood samples and laboratory results. Inclusion criteria were children aged from 9 months to 16 years and had received the full 3 compulsory doses of HBV vaccine during infancy. Signed written consents were obtained from each guardian Face to face interview was carried out with the parents or caretakers of the children. Adolescents above 10 years were also interviewed after their verbal assents which were obtained in the presence of their parents or class teachers. The questionnaire was used to collect data about child age, sex, date of birth and other demographic and socioeconomic variables. Data were also collected concerning children's' HBV vaccination and the available vaccination cards were revised for date and dose intervals of HBV vaccine. Socioeconomic status (SES) was determined according to Fahmy and El Sherbiny [13]. It depends on parents’ education, maternal working status, water source, sewage disposable, and availability of electricity and some modification of family income. Non-responders for the booster dose were further given 2 additional doses of HBV vaccine with 2 months interval in between. Out of 88 children proved to have nonseroprotective levels, 45 children participated and accepted to receive a booster dose of 10 μg monovalent Euvax HB vaccine intramuscularly in the front of the left thigh for children < 3 years and in the deltoid muscle for older children. A blood sample was withdrawn from each child for quantitative detection of anti-HBs one month and one year post–booster in order to assess their early and late anamnestic responses respectively. An anamnestic response was defined as rising in anti-HBs to ≥10 IU/L [14]. Three children who did not develop post-booster antiHBs level ≥ 10 IU/L were then offered two additional doses of Euvax HB vaccine (2nd vaccination series) 1 and 6 months post booster. One month later, a blood sample was withdrawn from only 2 children for quantitative detection of anti-HBs to assess their immune response.
Blood sampling and Laboratory Analysis About 3-5 ml blood sample was withdrawn aseptically from each participant. Serum samples were aliquoted into two labeled sterile cryo tubes and were stored at –20°C until laboratory examination. HBV markers detection was carried out in the Virology lab in the Microbiology Department,Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt. It was carried out using commercially available enzyme-linked immunoassays (ELISA, DiaSorinItaly) and according to the manufacturer instructions. Quantitative detection of serum anti-HBs and qualitative determination of serum Total HBV core antibody (anti-HBc) and hepatitis B surface antigen (HBsAg) was assessed. According to international
_______________________________________________________________________________________________________________________________ 220
http://www.mjms.mk/ http://www.id-press.eu/mjms/
Sami et al. Hepatitis B Seroprotection among Vaccinated Children in Red Sea Governorate _______________________________________________________________________________________________________________________________
standards, anti-HBs ≥ 10 IU/L was considered to be protective against HBV infection [14, 15]. Vaccines that developed an anti HBs level between 10-100 IU/L after the full vaccination dose are referred to as low responders while those above 100 IU/L are good responders [16]. Sero-positivity is defined as cutoff anti-HBs of 3.3 IU/L [17]. Breakthrough infection was defined as anti-HBs seropositivity in vaccinated subjects who were not chronically infected [18].
seroprotective level (< 10IU/L). As regards early postbooster anamnestic response, 75.6% developed a good anamnestic response, 17.8% developed low anamnestic response (10-99 IU/L) and 6.7% were non-responders. Table 1: Sero-protection rate among the studied children
Risk Factor
Data analysis and presentation Data entry was carried out on excel sheet and statistical analysis was performed using SPSS software program version 18.0 (SPSS Inc., Chicago). The geometric mean titer (GMT) was calculated to indicate the central tendency of anti-HBs titers in consideration of the skewed distribution of antiHBs level. For the calculation of the GMT, children who had an undetectable anti-HBs titer were assigned a nominal serum anti-HBs titer value of 0.05 IU/l [13]. The w2-test was performed for qualitative data and was presented by numbers and percentages. The ttest was performed for comparison between two means and one-way analysis of variance for more than two means. When data were not normally distributed, Mann-Whitney U test was used. The multivariate logistic analysis was performed to predict the risk factors significantly associated with non seroprotection and non-development of early and late anamnestic response. P value was considered statistically significant when its value was less than 0.05 and considered statistically highly significant when its value was less than 0.01.
Total n= 189
Baseline anti-HBs level (IU/L) Non seroSero-protection protection Anti-HBs ≥10 Anti-HBs -2 159 76 (47.8) 83 ≤ -2 22 8 (36.4) 14 WAZ > -2 176 81 (46.0) 95 ≤ -2 3 1 (33.3) 2 Lactation Breast fed 134 57 (42.5) 77 Artificially fed 29 17 (58.6) 12 History of hospital admission Yes 58 33 (56.9) 25 No 131 55 (42.0) 76 History of abscess incision Yes 12 5 (41.7) 7 No 174 82 (47.1) 92 HAZ = height for age Z score; WAZ = weight for age Z score.
(54.0) (52.8) (82.8) (56.8) (34.0) (39.3) (51.4) (53.2) (60.0)
0.870
< 0.001
0.317
(52.2) (63.6)
0.736
(54.0) (66.7)
0.189
(57.5) (41.4)
0.272
(43.1) (58.0)
0.058
(58.3) (52.9)
0.714
Out of 42 children who developed early, anamnestic response 41 (97.6%) were followed up one year later to assess the persistence of response (late anamnestic response). It was found that 31 children (75.6%) still retained their anamnestic response (anti-HBs ≥10IU/L) while 10 children (24.4%) had lost their protective level.
Results The total number of studied children was 189 (100 boys and 89 girls) aged 9 months to 16 years with a mean age of 9.6 years. None of the participants had an evidence of chronic HBV or breakthrough infection. Table 1 shows that the nonseroprotection level significantly increased with age (it was 17.2% for the age group < 5 years and 66% for the age group >10 years, P < 0.05). There was no significant difference in the seroprotection level as regards gender, socioeconomic status, and other studied variables. Only 45 children with non-seroprotection level received the booster dose and 93.4% of them developed an anamnestic response. Figure 1 presents the baseline seroprotection rate and postbooster anamnestic response rate among the studied children. At baseline, out of 189 studied children, only 44 (23.3%) had a good level of seroprotection (antiHBs ≥ 100 IU/L) and 88 (46.6%) had a non-
Figure 1: Baseline seroprotection and early anamnestic response rates among the studied children
Meanwhile, the two children who received the 2nd vaccination series developed a good level of
_______________________________________________________________________________________________________________________________ Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219-225.
221
Basic Science _______________________________________________________________________________________________________________________________
immune response (anti-HBs ≥100 IU/L). Both were boys aged 11 years. Table 2: Anamnestic response and anti-HBs GMT in relation to gender, age, and pre-booster level
N = 189 GMT ± SD
Early Anamnestic Response N = 45 GMT ± SD
Late Anamnestic Response N = 41 GMT ± SD
9.8 ± 13.5 12.1 ± 14.9 0.589
209.6 ± 12.2 249.0 ± 9.2 0.624
95.5 ± 21.3 39.3 ± 2.3 0.117
45.7 ± 9.5 3.6 ± 10.9 10 years P value Pre-booster level
Table 2 presents baseline, early and late anamnestic response anti-HBs GMT in relation to gender, age, and pre-booster level. There was no difference between both sexes as regard prebooster and post- booster (early and late anamnestic response) GMT anti-HBs. While children aged ≤ 10 years had significantly higher pre-booster antiHBs GMT than older children, post-booster (early and late) GMT anti- HBs did not differ among both age groups. When pre-booster non-seroprotection antiHBs levels were divided into seronegative (< 3.3 IU/L) and seropositive (≥ 3.3 IU/L), the post-booster early anamnestic response GMT was significantly higher among children with seropositive level of antiHBs than among those with seronegative level of antiHBs (848.6 ± 1.3 & 64.3 ± 18.0 respectively) P = 0.004. However, there was no statistically significant difference between both groups for late anamnestic response GMT. Table 3: Predictors of not seroprotection, early and late anamnestic responses using logistic analysis 95% CI Lower Upper
P value
® 3.616 8.509
1.363 3.648
9.592 19.848
0.010 < 0.001
® 4.7
2.1
10.4
< 0.001
Variables
AOR
At Baseline Age group < 5 years 5-10 years >10 years Early Anamnestic Response Baseline anti-HBs level ≥ 3.3 IU/L < 3.3 IU/L
Late Anamnestic response Baseline anti-HBs level ® ≥ 3.3 IU/L 1.4 3.0 < 3.3 IU/L 2.0 ®: reference group; AOR: adjusted odds ratio; CI: confidence interval.
< 0.001
Multivariate logistic analysis revealed that older age was the only significant predicting variable for having no seroprotective level, with AOR = 3.6 and 8.5 among children aged 5-10 and older age respectively compared to those < 5 years, P < 0.01. The significant predicting variable for not developing
an early anamnestic response or loss of late anamnestic response was baseline anti-HBs level < 3.3 IU/L with AOR 4.7 & 2.0 respectively and P70% [25, 26]. The seroprotection rate was higher among boys (54.0%) than girls (52.8%) and among children with higher socioeconomic status (60.0%) compared with others with very low socioeconomic status (39.4%), but with no statistically significant difference. Similarly, no statistically significant differences were reported as regards gender [5, 21, 22, 24]. However, Sami et al found that in Gharbeya Governorate in Lower Egypt among 762 children, the non seroprotection rate was significantly higher among girls (50.1%) compared to boys (33.6%) (P 6 years, while no statistical difference was found among children < 6 years [28]. The present study showed that 46.6% of studied children had non-seroprotective levels of anti-
_______________________________________________________________________________________________________________________________ 222
http://www.mjms.mk/ http://www.id-press.eu/mjms/
Sami et al. Hepatitis B Seroprotection among Vaccinated Children in Red Sea Governorate _______________________________________________________________________________________________________________________________
HBsat baseline and 93.4% of those receiving the booster dose developed an anamnestic response. Seventy-five percent of them developed good anamnestic response (anti-HBs ≥ 100 IU/L) and 6.7% were non-responders. Similarly, in Egypt, it was found that 91.7% of non-seroprotected children developed anamnestic response and 77.8% of them reported good response [27]. Moreover, Eldesoky et al found that 97.2% of the non-seroprotected children developed good anamnestic response [7]. A Turkish and an Italian study also reported that over 95% of non-seroprotected children developed an anamnestic response post booster [21, 22]. A lower percentage of children developed a postbooster anamnestic response in Iran (78.1%) and in Taiwan [24, 29]. Booster doses of hepatitis B vaccine after primary vaccination in immune competent individuals are currently not recommended by either the WHO or the European Consensus group on Hepatitis B Immunity. The decrease of antibody concentrations below seroprotection level or even below detection levels is not considered as an indicator of loss of protection [30]. The real threat may emerge when the vaccinated subjects begin to engage in high-risk behaviors for HBV transmission in areas of high endemicity. Boosters for certain highrisk groups or for individuals living in the areas of high endemicity may be a reasonable alternative [31-33]. In this study, post booster anamnestic was detected among 100% of non-seroprotected children having pre-booster level ≥ 3.3 IU/l compared to only 90.3% of those having pre-booster level < 3.3 IU/l (P > 0.05). Similarly but to a less extent, Steiner et al, reported that 90.5% of children who had antiHBs antibody concentrations > 3.3 IU/l reached the seroprotection level after receiving the booster dose compared to 81.0% of seronegative children [34]. In the current study, girls had higher prebooster and post-booster anti-HBs GMT compared with boys but with no statistically significant difference between both sexes (P > 0.05]. While children aged ≤ 10 years had significantly higher pre-booster antiHBs GMT than those aged >10 years (P < 0.05], but there was no difference between both age groups in the post-booster anti-HBs GMT. These results are similar to those of other studies in Alaska, Turkey, and Iran which found that pre-booster anti-HBs GMT significantly decreased with age [10, 21, 24). However, in two Iranian studies, it was found that the post-booster anti-HBsGMT among girls was significantly higher than among boys (P < 0.05] [23, 24]. The statistically significant difference between the mean antibody concentration before and after the booster dose shows the vigorous response of the immune system to the booster and suggests that the immunologic memory is good [24]. In the current study, 100% of the children ≤ 10 years and 91.1% of adolescents developed anamnestic response (P > 0.05). Similarly, in Alaska, 99% of children and 83% of adolescents [10] and
100% of children in Taiwan [32] developed an anamnestic response to a booster dose. Similar results were also reported by [21, 24]. They also found that there was no significant difference in postbooster anamnestic response rate as regards age. In contrast, the anamnestic response rate in Alaskan children decreased according to increasing age [10]. In the current study, the anamnestic response rate to the booster dose did not vary between boys and girls (91.3% and 95.5% respectively, P > 0.05). Similarly, in Gharbeya governorate, the anamnestic response rate was 90.1% among boys and 92.5% among girls, P > 0.05 [27]. On the contrary, Su et al found that Taiwanese adolescent females always had a greater anamnestic response rate than males (P < 0.001) [35]. In the present study, 75.6% of children still retained their anamnestic response after one year post- booster. This was also found in a study in Gambia where 80% of boosted participants still had detectable antibodies [8] and in Canada where 99.3% of subjects in the Engerix-B 10 [mu]g (EB) group and 100% in the Recombivax-HB 2.5 [mu]g (RB) group had detectable anti-HBs one year after the booster [31]. In this study after the booster dose was administered, 6.7% of children were non-responders and two out of the three children who failed to generate an early anamnestic response after receiving the booster dose, were offered another two doses of recombinant HBV vaccine. While 3% of Italian children and 4% of Italian recruits remained negative for anti-HBs, they offered to complete the second course of vaccination with two additional vaccine doses given at 1 and 6 months after the first booster injection [22]. Also, 3% of boosted participants in Gambia did not mount a detectable antibody response following a booster dose of HBV [8]. Samandari et al and Su et al reported that 28.7% and 31% of Alaskan and Taiwanese adolescents respectively did not respond to a booster dose. [10, 35] Logistic analysis for determining predictors of not seroprotection revealed that older age was the only significant predicting variable for having no seroprotective level while significant predicting variable for not developing an early anamnestic response or loss of late anamnestic response was baseline anti-HBs level < 3.3 IU/L. On the contrary, there was no significant difference as regards HBV booster non-response in subjects below or above 16 years of age in a study by Lu et al [32.] In another study by Wang and Lin, risk of non-response to booster vaccination was highest among adolescents who smoked cigarettes and chewed betel- quid [36]. The study concluded that long-term immunity exists among children who had complete series of hepatitis B vaccination during infancy even in the case of reduced or absent anti-HBs over time. HBV vaccine
_______________________________________________________________________________________________________________________________ Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219-225.
223
Basic Science _______________________________________________________________________________________________________________________________
is highly protective against HBV infection as evidenced by the absence of HBV infection in the vaccinated groups. The longer the time lapse after vaccination, the lower the seroprotection rate and the lower the mean anti-HBs. More than 93% of vaccinated individuals who lost protective levels of antibody developed a rapid anamnestic response when boosted and this indicates the presence of immune memory. Therefore, using routine booster doses of hepatitis B vaccine is not necessary to sustain at least 16 years of protection in immunized individuals.
results from a case–control study in Greater Cairo. International Journal of Epidemiology. 2009;38:757–765. http://dx.doi.org/10.1093/ije/dyp194 PMid:19420088
References
16. Shouval D. Hepatitis B vaccines. Journal of Hepatology. 2003;39:S70-76. http://dx.doi.org/10.1016/S0168-8278(03)00152-1
1. Huang C, Dai C, Chuang W, Ho C, Wu T, Hou N, Wang C, Hsieh M, Huang J, Lin Z, Chen S, Hsieh M, Wang L, Tsai J, Chang W, Yu M. HBV infection in indigenous children, 20 years after immunization in Taiwan: A community-based study. Elsevier Inc. Preventive Medicine. 2009;48:397–400. http://dx.doi.org/10.1016/j.ypmed.2009.02.002 PMid:19463479
17. Burgessa MA, McIntyrea PB, Hellardb M, Ruffc TA, Lefevred I, Bockd HL. Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine. 2010;28:2222–2226. http://dx.doi.org/10.1016/j.vaccine.2009.12.053 PMid:20056187
2. World Health Organization (WHO). Hepatitis B.1. Geneva, (WHO Fact sheet, No. 204. (http://www.who.int/mediacentre/factsheets/fs204/en/index.html, accessed 18 May 2009). 3. Talaat M, El-Sayed N, Kandeel A, Azab MA, Afifi S, Youssef FG, Ismael T, Hajjeh R, Mahoney FJ. Sentinel surveillance for patients with acute hepatitis in Egypt, 2001–04. Eastern Mediterranean Health Journal (EMHJ). 2010;16(2).
12. Youssef A, Yano Y, ZakiM E, Utsumi T, Hayashi Y. Characteristics of hepatitis viruses among Egyptian children with acute hepatitis. 2013: 1459-1465. 13. Fahmy SI, El-Sherbiny AF. Determining simple parameters for social classifications for health research. The Bulletin of the High institute of Public Health. 1983;18(5):95-103. 14. World Health Organization (WHO). Hepatitis B. WHO/CDS/CSR/mLYO/. 2002;2:1–76. 15. Zanetti A, Parlato A, Romanò L, Desole MG, Ferrera G, Giurdanella F et al. Challenge with a hepatitis B vaccine in two cohorts of 4-7-year-old children primed with hexavalent vaccines: an open-label,randomised trial in Italy. Vaccine. 2012; 30(39): 5770-5. http://dx.doi.org/10.1016/j.vaccine.2012.06.078 PMid:22789511
18. Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, JengBarry A, Sidibeh M, Jatta A, Moore SE, Hall AJ, Whittle H. Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One. 2013; 8(3):e58029. http://dx.doi.org/10.1371/journal.pone.0058029 PMid:23533578 PMCid:PMC3606345 19. Banatvala J. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000;355:561–65. http://dx.doi.org/10.1016/S0140-6736(99)07239-6
4. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B Virus Infection: Epidemiology and Vaccination. From the Epidemiology Branch, Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Accepted for publication March 28, 2006.
20. Salama II, Sami SM, Salama SI, Foud WA, Abdel Hamid AT, Said ZN. Persistence of protection to hepatitis B vaccine and response to booster dose among children and adolescents in Dakahleya- Egypt. Egyptian Journal of Immunology, 2014;21 (1): 13-26. PMid:25204041
5. Han K, Shao X, Zheng H, Wu C, Zhu J, Zheng X, Zhang Y. Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule. Human Vaccines & Immunotherapeutics. 2012;8:12,1845–1849. http://dx.doi.org/10.4161/hv.21818 PMid:22906933 PMCid:PMC3656074
21. Aypak C, Yüce A, Yıkılkan H, Görpelioğlu S. Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children. Eur J Pediatr. 2012;171:1761–1766. http://dx.doi.org/10.1007/s00431-012-1815-4 PMid:22895894
6. Chen D. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. Journal of Hepatology. 2009; 50:805–816. http://dx.doi.org/10.1016/j.jhep.2009.01.002 PMid:19231008 7. Eldesoky A, Mosaad Y, Zakria Y, Hamdy S. Protective immunity after hepatitis B vaccination. 2009; 10(2):68–71. 8. van der Sande MAB, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey SJ, Jeffries D, Hall AJ, Whittle HC. Long-Term Protection against Carriage of Hepatitis B Virus after Infant Vaccination. The Journal of Infectious Diseases. 2007; 193:1528–35. http://dx.doi.org/10.1086/503433 PMid:16652281 9. Zhu C, Liu P, Chen T, Ni Z, Lu L, Huang F, Lu J, Sun Z, Qu C. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine. 2011;29:7835–7841. http://dx.doi.org/10.1016/j.vaccine.2011.07.098 PMid:21816197 10. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, Bell BP. Differences in Response to a Hepatitis B Vaccine Booster Dose Among Alaskan Children and Adolescents Vaccinated During Infancy. Pediatrics. 2007;120(2): e373-e381. http://dx.doi.org/10.1542/peds.2007-0131 PMid:17636112 11. Jimenez AP, Sharaf El-Din N, El-Hoseiny M, El-Daly M, AbdelHamid M, El Aidi S, Sultan Y, El- Sayed N, Mohamed MK, Fontanet A. Community transmission of hepatitis B virus in Egypt:
22. Zanetti AR, Mariano A, Roman L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, Parlato A, Zamparo E, Zotti C, Stroffolini T, Mele A, and the Study Group. Long- term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366: 1379–84. http://dx.doi.org/10.1016/S0140-6736(05)67568-X 23. Hassan S, Ziba F. Antibody titre in Iranian children 6 years after hepatitis B vaccine administration. Vaccine. 2007; 25 (17):3511-4. http://dx.doi.org/10.1016/j.vaccine.2005.09.037 PMid:17400337 24. Yazdanpanah B, Safari M, Yazdanpanah S. Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran. Hepatitis Monthly. 2010;10(1):17-21. PMid:22308120 PMCid:PMC3270339 25. Liop LG, Alcoverro AA, Mas PC, Benedito MAR, Juan CG. [Anti-HBs titres after a vaccination program in children and adolescents. Should a booster dose be given?]. An Esp Pediatr. 2001; 54(1):32-7. http://dx.doi.org/10.1016/S1695-4033(01)786468 26. Behjati M, Mirhoseini N, Ayatollahi J. [A Survey of immune status of primary school age children, 7 years post hepatitis B vaccination]. J Shaheed Sadoughi Univ Med Sci. 2002;10(3):3-7. 27. Sami SM, Salama II, Rabah TM, El Etreby LA, Abdel Halim NF, Hemeida SA. Hepatitis B long-termseroprotection and the response to a challenging dose among vaccinated children in
_______________________________________________________________________________________________________________________________ 224
http://www.mjms.mk/ http://www.id-press.eu/mjms/
Sami et al. Hepatitis B Seroprotection among Vaccinated Children in Red Sea Governorate _______________________________________________________________________________________________________________________________
Gharbeya Governorate. Medical Research Journal. 2013;12:81– 87. http://dx.doi.org/10.1097/01.MJX.0000438131.28694.35 28. El-Sayed B, El-Guindi M, El-Shaarawy A, Salama EI, Sobhy GA. Long-term immunogenicity of hepatitis B vaccination in children. Zagazig J Occup Health Safety. 2009;2:17–28. 29. Wang L-Y, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBsnegative adolescents who had received primary vaccination 16 years ago. Vaccine. 2007; 7160– 7167. http://dx.doi.org/10.1016/j.vaccine.2007.07.022 PMid:17707557 30. Poorolaja lJ, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-termprotection provided by hepatitis B vaccine and need for booster dose: A meta-analysis. Vaccine. 2010;28:623–631. http://dx.doi.org/10.1016/j.vaccine.2009.10.068 PMid:19887132 31. Bernard D, Vladimir G, Nicole B, Philippe DW, Richard M, Gisele T, Gaston DS. Comparative Long Term Immunogenicity of Two Recombinant Hepatitis B Vaccines and the Effect of a Booster Dose Given After Five Years in a Low Endemicity Country. Pediatric Infectious Disease Journal. 2005;24(3):213-218. http://dx.doi.org/10.1097/01.inf.0000154329.00361.39 32. Lu CY1, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, Su IJ, Kuo HS, Huang LM, Chen DS, Lee CY Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis. 2008;197(10):1419-26. http://dx.doi.org/10.1086/587695 PMid:18444799 33. Saygun O, Eyigun CP, Avci IY, Kisa U, Pahsa A. Investigation (In Vivo and In Vitro) of Booster Dose Vaccine Requirement for Long-Term Protection against Hepatitis B Virus Infection Turk J Med Sci. 2009;39(2): 173-177. 34. Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet J-M, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infectious Diseases 2010. 2010; licensee Bio Med Central Ltd. http://www.biomedcentral.com/1471-2334/10/9. 35. Su FH, Cheng SH, Li CY, Chen JD, Hsiao CY, Chien CC, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine. 2007;25:8085–8090. http://dx.doi.org/10.1016/j.vaccine.2007.09.013 PMid:17920732 36. Wang LY, Lin HH. Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Journal of Hepatology. 2007;46:1018–1025. http://dx.doi.org/10.1016/j.jhep.2007.01.022 PMid:17399842
_______________________________________________________________________________________________________________________________ Open Access Maced J Med Sci. 2016 Jun 15; 4(2):219-225.
225
